Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05533203
Other study ID # HTB-B003-I
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date August 8, 2022
Est. completion date March 1, 2024

Study information

Verified date September 2022
Source Shanghai Humantech Biotechnology Co. Ltd
Contact Guoyou Chen, Ph.D.
Phone +86 13601923503
Email guoyouchen@humtech.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I clinical trial is to evaluate the safety of Prodencel (an autologous dendritic cell therapeutic tumor vaccine.) in patients with metastatic castration-resistant prostate cancer (mCRPC).


Description:

This is a single arm pilot study to evaluate the safety of delivering a dendritic cell vaccine in fifteen to twenty-four (n=15-24) adult patients diagnosed with prostate adenocarcinoma after novel androgen-deprived therapy and docetaxel chemotherapy failure. The study is constructed in a 3+3 design for three steps of dose escalation with rigorous and mandatory safety monitoring. Subjects received the vaccine at a dose of 5-15×10^6 cells every two weeks for a total of 3 doses. A dose from cohort 1-3 is recommended for booster immunization every 4 weeks until disease progression or intolerance, to evaluate the safety and tolerability of the booster immunization of Prodencel. Subjects will be monitored for adverse events as dictated by CTCAE version 5.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date March 1, 2024
Est. primary completion date August 30, 2023
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically prostate adenocarcinoma, exclusion of the initially diagnosed neuroendocrine or small-cell carcinoma. - Subjects with metastatic castration-resistant prostate cancer (mCRPC) who have failed novel androgen-deprived therapy and docetaxel chemotherapy. The previous antitumor treatment is =4 weeks prior to first dose. - The previous clinical trials is =30 days prior to screening; Under the circumstance of previous clinical trials=3 months , the pre-trial drug cannot interfere the safety and efficacy of current trial judged by the investigators. - Age =18 years old when signing ICF, male, weight =50kg. - Screening ECOG performance status is =2. - Written information consent provided prior to the initiation of study procedures with cooperation during the follow-up. Exclusion Criteria: - Treatment requirement of Olaparib with the confirmed BRCA gene mutation. - Rechallenge of docetaxel or other chemotherapy. - Imminent Radiotherapy with radium-223. - Plan to participate in other clinical trials. - Pathological long bone fracture (cortical erosion > 50% on imaging) or spinal cord compression. - History of other malignancies in the past 5 years with the exception of the following:cancer disease free=5 years or squamous or basal cell skin carcinoma. - Systemic therapy of immunosuppressive agents (such as cyclosporine, tacrolimus, rapamycin, and azathioprine, etc.) within one month prior to screening. - Use of oral, intramuscular or intravenous corticosteroids within 28 days prior to enrollment. Short-term use of corticosteroids are allowed to prevent reactions for imaging studies. Use of inhaled corticosteroids for breathing insufficiency (chronic obstructive pulmonary disease) and topical steroids are allowed. - Positive infectious disease screening. Active HBV hepatitis (defined as positive HBsAg with HBV-DNA = upper limit of normal (ULN)); Active hepatitis C (defined as HBV-Ab =ULN); Positive COVID-19;Human immunodeficiency virus (HIV) infection with HIV-Ab =ULN;Positive syphilis with TP-Ab=ULN. - Myocardial infarction, unstable angina pectoris, cardiac surgery or interventional therapy within 6 months prior to enrollment. Congestive heart failure, atrial fibrillation or other poorly controlled arrhythmias. - Cerebrovascular events (including hemorrhagic, ischemic, transient ischemic attack), craniocerebral surgery and unexplained loss of consciousness occurred within 6 months before enrollment. - Presence of the malignant pleural effusion or malignant ascites. - History of severe allergic reactions or allergies to the ingredients of Prodencel. - Abnormal screening hematologic function: white blood cell count (WBC)<3.0×109/L, neutrophil count (NEUT)<1.5×10^9/L, platelet count (PLT)<100×10^9/L, hemoglobin (Hb)< 100g/L. - Abnormal screening coagulation function: prothrombin time (PT) =ULN, international normalized ratio (INR) =ULN, thrombin time (TT) =ULN. - Abnormal screening liver and kidney function: total bilirubin (TBIL) > 1.5ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5ULN; serum creatinine (SCr) > 1.5 ULN. - History of splenectomy. - Presence of primary or secondary immunodeficiency disease. - History of uncontrolled seizures, central nervous system disorders, or psychotic loss of cognition. - History of chronic alcohol or drug abuse within 6 months prior to screening. - Unstable systemic diseases, such as active infection, liver cirrhosis, chronic renal failure, severe chronic lung diseases, etc. - Clinically severe pericardial effusion. - Not suitable for leukapheresis. - For any other reasons, the patients are believed not suitable for participation in this study by investigators.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Prodencel; an autologous dendritic cell therapeutic tumor vaccine
Subcutaneous injection, each injection point should not exceed 1ml.

Locations

Country Name City State
China Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Shanghai Humantech Biotechnology Co. Ltd Shanghai Changhai Hospital,The First Affiliated Hospital of Naval Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment-Emergent Adverse Events (AEs) during Induction Immunization AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Up to 2 weeks after the third administration
Secondary Incidence of Treatment-Emergent Adverse Events (AEs) during Booster Immunization AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Up to approximately 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04986423 - ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT05489991 - A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase 1/Phase 2
Active, not recruiting NCT05521412 - EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T Phase 1/Phase 2
Terminated NCT04556617 - PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1/Phase 2
Completed NCT02125357 - Sequencing Abiraterone and Enzalutamide in mCRPC Phase 2
Recruiting NCT06052306 - A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) Phase 1
Recruiting NCT05917470 - A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. Phase 1/Phase 2
Recruiting NCT05519449 - Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) Phase 1
Terminated NCT05301062 - A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Recruiting NCT05383079 - Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT04060394 - Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Phase 1/Phase 2
Completed NCT01942837 - Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer Phase 2
Recruiting NCT05458544 - [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application Phase 1/Phase 2
Withdrawn NCT04879589 - Phase 1 Study of ATRS-2002 in Healthy Male Adults Phase 1
Recruiting NCT03230734 - Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer Phase 2
Recruiting NCT05116579 - Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
Active, not recruiting NCT03732820 - Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer Phase 3
Recruiting NCT05005728 - XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05762536 - Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC Phase 2